CD8A and myeloid sarcoma: Similar findings were reported in another MS cohort, where CD20+CD3+ cells represented 18.4 ± 2.3% of all CD20+ cells and included a higher proportion of CD8+ (58.9 ± 2.6%) than CD4+ (35.1 ± 2.4%) cells, opposite to the entire CD3+ T cell compartment (29.2 ± 2.4% vs. 69.3 ± 2.4%, respectively) [17].